Dr. MacNeil is the Lead Consultant at Jaguar Pharma Consulting LLC, where he provides Early Drug Discovery consulting services for Academic Groups, Biotech Companies, and Research Foundations. For each client, he provides a customized research plan from an initial lead to the selection of a Clinical Candidate. He recommends the optimal mix of internal and CRO resources to assure a time- and resource-efficient plan from bench to the clinic. He is also a member of the Alzheimer’s Drug Discovery Foundation Scientific Review Board.
Dr. MacNeil has extensive experience in Early Drug Discovery and Development at major pharmaceutical companies. During his research career he rose from a bench level scientist to Director of In Vitro Sciences where he was responsible for in vitro assay support to over 40 research programs at Merck’s NJ research sites. He has a proven record of delivering development compounds, including expertise in target identification, target validation, project support, and discovery team leadership. Dr. MacNeil initiated seven programs that delivered compounds for development; four achieved clinical proof of concept. He has deep capability in G-protein coupled receptors (GPCR), neuropeptides, energy homeostasis, neurodegeneration, and metabolic diseases. He is an expert at optimizing internal and external in vitro assays to support Lead Identification and Lead Optimization. He was responsible for 13 GPCR programs including agonist, antagonist, inverse agonist, allosteric modulators, and biased ligand projects. Dr. MacNeil has successfully managed international collaborations with partners in Japan, India, China, Germany and Denmark. He is recognized as an expert in cell-based assay development, assay validation, and CRO selection.
Jaguar Pharma Consulting offers consulting services for all aspects of Early Drug Discovery. These include: Target ID and Validation, in vitro Assay Development and validation, Screening Assay Development, compound profiling Assay validation and data QC, compound selection criteria for in vivo POC studies, and compound selection criteria for clinical candidate selection. In addition, I provide
Dr. MacNeil is an expert in in vitro cellular assays, in particular GPCR assays, with therapeutic experience in Diabetes, Obesity, Hypertension, Cardiovascular disease, Respiratory diseases, Fibrotic diseases, Oncology, and CNS diseases such as Alzheimer's and Parkinson's.
I provide expert consulting services to Biotech companies, academic groups, and Disease Research Foundations for optimizing Drug Discovery Research Plans, focusing on the appropriate in vitro pharmacology in Early Drug Discovery: from Target ID, to Lead ID, to in vivo POC, to selection of development compounds. I have extensive on site experience selecting and managing CROs for Early Drug Discovery. I am an expert in GPCR biology and in vitro cell based assays, with therapeutic experience in multiple disease areas including: Diabetes, Cardiovascular Disease, Obesity, Hypertension, Oncology, Respiratory diseases, Alzheimer's Disease and Parkinson Disease.
Optimal CRO Selection
I have extensive on-site experience reviewing the capabilities, abilities, and data quality of CROs in Asia, Europe and the US. Thus I can select the optimal CRO to support Early Drug Discovery efforts such as screening, in vitro assay development, assay transfer and validation, and compound profiling.
Jaguar Pharma Consulting has not received any reviews.
Jaguar Pharma Consulting has not received any endorsements.